JUNS jupiterneurosciences.com Profit After Payment of Taxes

Official company branding of Jupiter Neurosciences, Inc. (JUNS)

Jupiter Neurosciences Inc (JUNS) maintains a strong scientific foundation in neurodegeneration that secures physician trust, as evidenced by the company's marginal income, which currently stands at approximately -0.01. While the strategy is complemented by process optimization via third-party contractors in manufacturing and logistics, the focus on a single molecule creates high binary risk for the asset prior to the drug's commercial launch.

Jupiter Neurosciences, Inc. (JUNS) Company Net Income: for the period 12/04/2024 - 10/30/2026

Comprehensive metric breakdowns and analytics for Jupiter Neurosciences (JUNS)

- stock value and consensus price forecast:
Market Price jupiterneurosciences.com|JUNS - Price Target Chart
- market capitalization data:
Market Value Jupiter Neurosciences Inc|JUNS - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share Jupiter Neurosciences|JUNS - Company Book Value|Market Capitalization to Net Assets jupiterneurosciences.com|JUNS - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Jupiter Neurosciences Inc|JUNS - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Jupiter Neurosciences, Inc.|JUNS - Company Aggregate Debts|Debts to Book Value Jupiter Neurosciences Inc|JUNS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Jupiter Neurosciences|Intermediate Coverage Ratio jupiterneurosciences.com
- earnings and market multiples details:
JUNS - Company Net Income
Fundamental valuation:JUNS jupiterneurosciences.com
Mass-produced product of jupiterneurosciences.com

This indicator measures the net daily financial result, stripped of market volatility, allowing investors to identify hidden systemic risks prior to the publication of official reports. By analyzing the bottom line of Jupiter Neurosciences Inc (JUNS), one can assess the effectiveness of investments in the small molecule platform for combating CNS diseases, where the stability of this metric determines the pace of commercial pharmaceutical market capture and capital liquidity.

Main competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|RGC (regencellbioscience.com) - Profit After Payment of Taxes|Net Income AXSM (Axsome Therapeutics, Inc.)|Net Profit ACADIA Pharma (ACAD)|Company Net Income Xenon Pharmaceuticals Inc XENE|VKTX (Viking Therapeutics Corp) - Profit After Tax|Supernus Pharmaceuticals - Net Profit|Net Financial Result catalystpharma.com CPRX|DNLI (Denali Therapeutics Inc.) - Net Income|HRMY: Profit After Payment of Taxes|BHVN (Biohaven Pharmaceutical) - Net Profit|Company Net Income Amylyx Corp AMLX|Company Net Income Trevi Therapeutics (TRVI)|PRAX (praxismedicines.com) - Final Profit|Anavex Life Sciences Corp. - Net Income|Final Profit CBLL|PRTA - Company Net Income|ALEC (Alector, Inc.) - Company Profit|ANNX: Net Profit|Company Net Income Omeros (OMER)|Net Income NGNE|Net Profit AC Immune S.A.|Company Net Income Voyager Pharma (VYGR)|NMRA (Neumora Corp) - Final Profit|Company Net Income Scilex Holding Company SCLX|tevogen.com (TVGN) - Company Net Income|ACOG - Company Net Income|Net Financial Result cogrx.com CGTX|IKT: Net Profit|Net Income Cassava Pharma|ASRT (Assertio Holdings) - Net Profit|Coya (COYA) - Net Financial Result|Net Profit VTGN|OVID - Company Net Income|Company Net Income Acumen Pharma ABOS|CRVO: Company Profit|Alterity Therapeutics Ltd - Net Profit|Clene Inc. (CLNN) - Net Income|PEPG: Net Profit|Company Net Income Relmada Therapeutics Inc (RLMD)|Company Net Income Annovis Bio Corp|Grace Tx (GRCE) - Net Financial Result|Net Income AIFF (Firefly Neuroscience, Inc)|KLTO (anewmeds.com) - Final Profit|Net Profit NRSN (NeuroSense Therapeutics Ltd.)|Net Financial Result Reviva Pharmaceuticals Holdings Inc. (RVPH)|MTVA - Company Net Income|NRXS (NeurAxis Inc) - Company Profit|HSDT: Net Profit|Net Income Passage Bio|Company Net Income Neuphoria Therapeutics, Inc.|NERV (Minerva Neurosciences Inc) - Profit After Payment of Taxes|Net Income ATHA (Athira)|Net Profit Addex (ADXN)|Company Net Income Alzamend Neuro ALZN|CYCN: Company Profit|PTIX - Company Net Income|Net Financial Result Pasithea Therapeutics KTTA|cortigent.com (CRGT) - Company Net Income|Company Profit ATXI|BCLI (Brainstorm Cell) - Net Profit|Company Net Income caratherapeutics.com CARA|Net Income CHRO (Chromocell Therapeutics Corp.)|Net Profit eliemtx.com (ELYM)|Company Net Income Intra-Cellular Therapies, Inc. ITCI|Final Profit LBPH|MRNS - Company Net Income|Company Net Income nkgenbiotech.com|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|SAGE: Profit After Payment of Taxes|Net Income SNPX|Net Profit Trevena Inc|Company Net Income Vigil Neuroscience (VIGL)|WENA: Profit After Tax|Net Profit CERE (Cerevel Therapeutics, Inc.)